NASDAQ · Biotechnology
GILD
Gilead Sciences, Inc · $177.86B
147.60
+2.90%
Price
23 sessions shownTechnicals
from daily closesRSI · 14 day
79.6
Avg true range · 14d
2.80%
Volatility · 20d annualised
26.3%
Trend · 20d vs 50d
—
vs 20-day average
9.63%
vs 50-day average
—
vs 200-day average
—
200-day average
—
Internals
where it sits, and how hard it is being traded52-week low
108.46
52-week high
157.29
Volume vs its 20-day avg
0.96×
Beta vs the market
0.34
Sitting 80% of the way up its 52-week range (108.46 → 157.29)
Swings
prices it actually turned at — highest or lowest of the surrounding 11 sessionsTurned down · Jul 28
136.26
Turned down · Aug 5
137.80
Fundamentals
P/E
—
Fwd P/E
—
P/S
5.58
P/B
6.71
EV/EBITDA
17.66
ROE
-16.3%
ROA
-5.8%
Gross margin
79.6%
Net margin
—
Debt / equity
1.10
Rev growth
5.5%
EPS growth
23.1%
Earnings
Next report
Oct 28, 2026
EPS expected
2.21
Beat in last 4
4 of 4
2026-06-30reported -6.75 vs -7.38 expected+8.5%
2026-03-31reported 2.03 vs 1.95 expected+4.0%
2025-12-31reported 1.86 vs 1.85 expected+0.7%
2025-09-30reported 2.47 vs 2.17 expected+13.7%
Analyst coverage
37 analysts · as of 2026-08-01Strong buy
9
Buy
21
Hold
7
Sell
0
Strong sell
0
News
stories naming this company, last 21 daysEvery figure here is measured from live market data as of Aug 19, 08:10 PM. Nothing is estimated or filled in — where a figure shows — the source had no value for it, and a section you don’t see had no data at all. This describes what the market has already done. It is not a forecast, and not financial advice.